On August 19, SKB BIO declined 3.04% in regular trading, trading at HK$525.5/share, with turnover of HK$88.28 million. The stock pulled back after gaining approximately 4% in the prior session on better-than-expected interim results.

On the news front, while the company reported H1 net profit of RMB 388 million — a turnaround from a loss of RMB 145 million in the year-ago period — Goldman Sachs flagged that the profit was primarily driven by one-time items, including a RMB 702 million settlement payment from MediLink and a RMB 140 million US withholding tax refund, triggering profit-taking. Product sales rose 112% year-over-year to RMB 657 million, supported by the inclusion of core product sacituzumab tirumotecan (sac-TMT) in the national medical insurance program. Despite the pullback, UBS raised its target price to HK$678 reiterating a Buy rating, while CLSA lifted its target to HK$626.4, citing product sales that exceeded expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)